Exercise News and Research

Latest Exercise News and Research

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Ajinomoto AminoScience LLC (AAS) today announced that it has confirmed GRAS (Generally Recognized As Safe) status of its AjiGRAS-Leucine, meeting the safety standards demanded by the US Food and Drug Administration (FDA). As the only formulation of Leucine currently with FDA acknowledged GRAS status, Ajinomoto's AjiGRAS-Leucine is the first amino acid to be allowed as an ingredient for use in conventional foods like non-milk and milk based meal replacements, sports and isotonic beverages, vitamin enhanced waters, and meal replacement bars, at levels of 0.5 to 3 grams per serving.

16 Jul 2010

Citizens Bank, HealthPlus of Michigan engage employees in workplace wellness program

Two mid-size companies headquartered in Flint—Citizens Bank and HealthPlus of Michigan—recently put their heads together to creatively engage employees in a workplace wellness program.

16 Jul 2010

An overview of heart palpitations from Mayo Clinic

Almost everyone feels occasional heart palpitations -- a change in the heart's rhythm. Palpitations range from what feels like a skip, flip or bump in the heart's rhythm to a sustained, racing heartbeat.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Rapid weight loss the best: Study

Researchers have now shown that the best way to lose weight is to lose a lot of it at once contrary to popular belief even among doctors that weight should be lost slowly.

15 Jul 2010

Type 1 diabetes affects athletic performance, new study finds

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels.

15 Jul 2010

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

IBM today announced plans to enlist some of the company's leading scientists and technologists to help medical practitioners and insurance companies provide high-quality, evidence-based care to patients. As part of this initiative, IBM is collaborating with clinicians in medical institutions and hiring medical doctors to work alongside its researchers to develop new technologies, scientific advancements and business processes for healthcare and insurance providers.

15 Jul 2010

Dance works all over for health, researcher says

Can elderly Latinos who have limited mobility and face elevated risks of disability dance their way to better health? A University of Illinois at Chicago researcher wants to find out.

15 Jul 2010

Lantheus Medical Imaging, JBCPL partner to launch DEFINITY ultrasound contrast imaging agent in India

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the launch of its ultrasound contrast imaging agent, DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, in India. The company has signed a multi-year agreement with Mumbai-based J.B. Chemicals & Pharmaceuticals, Ltd. for the distribution and marketing of DEFINITY® in the Indian marketplace.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

EpiCept increases exercise price of June 2010 Warrants to $1.64 per share

EpiCept Corporation has amended the exercise price of its Series A Warrants and Series B Warrants sold in June 2010 from $1.57 per share to $1.64 per share. The exercise price was amended by Amendment No.1 dated as of July 8, 2010, to the Securities Purchase Agreement between EpiCept and each of the purchasers signatory thereto, which amended the Securities Purchase Agreement dated June 25, 2010 between EpiCept and each of the purchasers signatory thereto.

15 Jul 2010

OraVerse MAA accepted for review in five key European countries

Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.

14 Jul 2010

Diet and exercise can reduce severity of hot flashes in overweight, obese women

A new study shows that overweight and obese women who suffer from hot flashes can reduce the severity of their hot flashes if they lose weight through diet or exercise.

14 Jul 2010

IFH delivers summer package of new software features to Expresso bikes worldwide

Interactive Fitness Holdings, announced that it has delivered a summer package of new software features to all networked Expresso bikes worldwide.

14 Jul 2010

Neptune first-quarter 2010 revenue up by 45% to $4,162,000

Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the three-month period ended May 31, 2010, appoints IR firm and updates on options and warrants.

14 Jul 2010

Russians show less distress compared to Americans: Research

Dostoyevsky and Tolstoy portrayed Russians as a brooding, complicated people, and ethnographers have confirmed that Russians tend to focus on dark feelings and memories more than Westerners do. But a new University of Michigan study finds that even though Russians tend to brood, they are less likely than Americans to feel as depressed as a result.

14 Jul 2010

Loyola primary care physicians honored with Blue Ribbon rating from Blue Cross and Blue Shield

Loyola University Health System primary care physicians recently received a Blue Ribbon rating from Blue Cross and Blue Shield. This honor is given to physicians who have received a satisfaction rate of 85 percent or higher based on a member survey.

14 Jul 2010

Therapeutic workbook to facilitate healing process in Haitian children

"When children can tell their stories about a traumatic event in their own words or pictures and at their own speed, healing can begin," says Dr. Jodie Kliman, psychologist and professor at the Massachusetts School of Professional Psychology (MSPP) in Boston. That is why Kliman led MSPP's collaboration with the Children's Psychological Health Center (CPHC) in San Francisco and Ekol Akasya (Acacia School) in Haiti to create a workbook to facilitate that healing process in Haitian children and to identify those at greatest risk for long-term emotional problems.

14 Jul 2010

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

OSI Pharmaceuticals, Inc. announced today that all of its 2% Convertible Senior Subordinated Notes due 2025 have been surrendered for conversion, as provided for in the Indenture governing the notes. As a result, no 2% Notes remain outstanding and the Company has terminated the Offer to Purchase the 2% Notes that the Company was required to make pursuant to Section 3.9 of the Indenture.

14 Jul 2010

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

Exercise News and Research

Latest Exercise News and Research

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Citizens Bank, HealthPlus of Michigan engage employees in workplace wellness program

An overview of heart palpitations from Mayo Clinic

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Rapid weight loss the best: Study

Type 1 diabetes affects athletic performance, new study finds

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

Dance works all over for health, researcher says

Lantheus Medical Imaging, JBCPL partner to launch DEFINITY ultrasound contrast imaging agent in India

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

EpiCept increases exercise price of June 2010 Warrants to $1.64 per share

OraVerse MAA accepted for review in five key European countries

Diet and exercise can reduce severity of hot flashes in overweight, obese women

IFH delivers summer package of new software features to Expresso bikes worldwide

Neptune first-quarter 2010 revenue up by 45% to $4,162,000

Russians show less distress compared to Americans: Research

Loyola primary care physicians honored with Blue Ribbon rating from Blue Cross and Blue Shield

Therapeutic workbook to facilitate healing process in Haitian children

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Exercise News and Research

Latest Exercise News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in